Friday, 19 Jul 2019

You are here

Safety Concerns Offset the Modest Improvements of Tanezumab in Osteoarthritis

JAMA reports that although tanezumab is modestly effective in moderate to severe osteoarthritis (knee or hip), with statistically significant improvements in pain and physical function, the tanezumab (TNZ) treated patients had more joint safety events and total joint replacements than patients treated with placebo.

Tanezumab is an investigational humanized monoclonal antibody that binds and inhibits nerve growth factor (NGF) and is being developed by Pfizer and Eli Lilly and Company.

In this trial a total of 698 hip or knee OA patients (refreactory to standard analgesic therapies) were randomized to receive placebo or 2 different dosing regimens of subcutaneous tanezumab given at 8-week intervals. The co–primary end points were the 16 week change in Western Ontario and McMasters Universities Osteoarthritis Index (WOMAC) Pain (0-10), WOMAC Physical Function (0-10) and patient global assessment of osteoarthritis (PGA-OA) (1-5) scores.

The mean age was 60.8 years; 65.1% women), and 84% completed the trial.  The results from baseline to 16 weeks are shown below:

DoseTNZ 2.5mgTNZ 2.5/7.5PBO

WOMAC Pain

7.1 to 3.6 (P=0.01)*

7.3 to 3.6 (P=0.002)*7.3 to 4.4
WOMAC Function7.2 to 3.7 (P=0.007)*7.4 to 3.6 (P<0.001)*7.4 to 4.5
PGA-OA3.4 to 2.4 (P=0.01)*3.5 to 2.4 (P=0.004)*3.5 to 2.7

*p Values compared to placebo

Rapidly progressive OA occurred only in tanezumab-treated patients (2.5 mg: n = 5, 2.2%; 2.5/5 mg: n = 1, 0.4%).

The incidence of total joint replacements was 8 (3.5%), 16 (6.9%), and 4 (1.7%) in the tanezumab, 2.5 mg; tanezumab, 2.5/5 mg; and placebo groups, respectively.

Although statistically significant, the risk of rapidly advancing joint damage with this nerve growth factor inhibitor questions the practicality and utility of tanezumab for treatment of osteoarthritis.

 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Intraarticular Capsaicin in Knee Osteoarthritis

A novel compound, synthetic trans‐capsaicin (CNTX‐4975), has been studied as an intraarticular injection and shown to significantly reduce pain in patients with chronic moderate‐to‐severe osteoarthritis of the knee. A phase II, multicenter, double‐blind study enrolled 172 knee OA patients between the ages of 45–80 years. Patients were randomized to receive either intraarticular placebo, or a high‐purity synthetic trans‐capsaicin CNTX‐4975 0.5 mg, or CNTX‐4975 1.0 mg.

Increased Risk of Cardiovascular Death in Hip and Knee Osteoarthritis

Hip and knee osteoarthritis patients have been shown to have increased mortality rates from cardiovascular events when compared to the general population.

The study included patients in the Skåne Healthcare Register from southern Sweden who were 45–84 years old and seen over 2004-2014. Overall, there were 15,901 such patients in the study.

Benefits vs Harms for Osteoporosis Drug Continuation or Discontinuation

While it is clear that long-term bisphosphonate therapies reduce fracture risk in women with osteoporosis, it is unclear how to counter-balance these benefits against rare serious harms and how to optimize therapeutic benefits with appropriate drug holidays. A systematic analysis of 48 studies compared long-term osteoporosis drug treatment (ODT) (>3 years) versus control versus ODT continuation versus durg discontinuation, to examine incident fractures or harms.

Mortality from Falls in the Elderly

JAMA reports that there is a trend of increasing mortality from falls in older US adults between 2000 to 2016 and that mortality rates are increased with increasing age. 

Knee Injuries Increases Osteoarthritis Risk

A systematic review of the medical literature shows anterior cruciate ligament (ACL), meniscus or combined ACL and meniscus injury significantly increases the risk of future knee osteoarthritis (OA).

The metanalysis comprised 53 studies and nearly 1 million participants, including 185,219 with ACL injury (mean age 28 years), 83,267 with meniscal injury (mean 38 years) and 725,362 with combined injury (mean 31 years).